Ideeea Therapeutics

IDEAYA Biosciences is a clinical-stage precision medicine company focused on the discovery and development of targeted therapeutics for cancer patients selected using molecular diagnostics. The company's core expertise lies in synthetic lethality, an approach that identifies and targets genetic vulnerabilities unique to cancer cells while sparing healthy tissue. IDEAYA's lead product candidate, darovasertib, is a potent and selective small molecule PKC inhibitor currently in registrational trials for the treatment of uveal melanoma. Their robust pipeline also includes first-in-class programs targeting MAT2A, PARG, and Werner Helicase, supported by strategic partnerships with global pharmaceutical leaders such as GSK.